Adamed Group

Adamed Group, founded in 2010, is a pharmaceutical company that includes Adamed, Pabianickie Zakłady Farmaceutyczne Polfa, and Adamed Consumer Healthcare among other entities. The group operates in the healthcare industry, focusing on pharmaceuticals and consumer healthcare products. Its primary business activities revolve around research, development, production, and distribution of pharmaceuticals and healthcare solutions. With a diverse portfolio of products and services, Adamed Group aims to improve the quality of life and well-being of patients by providing innovative and high-quality healthcare solutions.

Marcin Szczecinski

Investment Manager

4 past transactions

Inuru

Series A in 2023
Inuru GmbH, founded in 2016 and headquartered in Berlin, Germany, specializes in the manufacturing of inks for printing thin organic light-emitting diodes (OLED). The company aims to democratize lighting by making OLED technology affordable and accessible, particularly for packaging, advertising, and the print industry. By utilizing advanced printing technology, Inuru significantly reduces production costs by up to 95%, facilitating the integration of lighting and displays into various applications. Their products, including low-cost OLED labels, are already being utilized by notable clients such as CATTIER, COCA COLA, and DISPLATE. Inuru is also expanding its product offerings into clothing and medical applications, and operates a fully automated OLED manufacturing line in Germany. Their innovative approach enables eco-friendly illuminated solutions, allowing for enhanced visibility and information delivery across diverse surfaces.

Apeiron Synthesis

Seed Round in 2022
Apeiron Synthesis specializes in the development and manufacturing of modern catalysts with extensive applications in pharmaceuticals, flavors and fragrances, as well as the production of polymers and rubber. The company boasts a diverse portfolio of patented and patent-pending catalysts tailored for metathesis processes, which are critical for various industrial applications. By focusing on delivering process-specific catalysts, Apeiron Synthesis aims to enhance value for clients throughout the entire research and development cycle, from implementation to production.

Goodsleeper

Pre Seed Round in 2022
Goodsleeper is a pioneering sleep medicine application focused on enhancing sleep quality through cognitive behavioral therapy for insomnia (CBT-I). Recognized as the primary evidence-based treatment for insomnia, CBT-I offers more effective results than traditional sleep medications by addressing the underlying factors contributing to sleep disturbances. Through its application, Goodsleeper provides users with a structured approach to implementing CBT-I techniques, enabling them to analyze their sleep issues and develop personalized sleep improvement plans. The application also incorporates digital tools to facilitate the practical application of these therapeutic methods, allowing individuals to safely and effectively manage their insomnia.

Telemedi

Series A in 2021
Telemedi is a healthcare technology company established in 2014. It specializes in providing businesses with a comprehensive, user-friendly digital healthcare platform. This platform offers modules such as telemedicine for remote consultations, automated triage using artificial intelligence, monitoring of medical devices, and API integrations for seamless connectivity with other systems. Telemedi is renowned for its advanced digital healthcare solutions and serves as a trusted partner to various businesses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.